[Principal therapeutic uses of monoclonal antibodies in oncology]

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Monoclonal antibodies represent a significant advancement in cancer therapy.
• These agents target tumor-specific antigens, which are often overexpressed on cancer cells compared to normal cells.
• Monoclonal antibodies can be conjugated to cytotoxic drugs or radioactive compounds, or used as non-conjugated agents.

Purpose of the Study:

• To review the development and application of monoclonal antibodies in oncology.
• To highlight key examples of currently used and investigational monoclonal antibodies.
• To emphasize the importance of targeted antigen approaches in cancer treatment.

Main Methods:

• Review of existing literature on monoclonal antibody-based cancer therapies.
• Identification of key monoclonal antibodies used in clinical practice and under investigation.
• Categorization of monoclonal antibodies based on their mechanism of action (conjugated vs. non-conjugated).

Main Results:

• Several monoclonal antibodies are approved for cancer treatment, including Herceptin (trastuzumab) targeting HER2, Erbitux (cetuximab) targeting EGFR, and MabThera (rituximab) targeting CD20.
• Herceptin and MabThera have demonstrated improved survival in breast carcinoma and lymphoma, respectively.
• New agents targeting EGFR and VEGF are under investigation for various cancers, including colon, head and neck, and others.

Conclusions:

• Monoclonal antibodies targeting tumor antigens have a significant impact on cancer treatment outcomes.
• The progress in selectively targeting tumor antigens highlights the potential of these approaches in oncology.
• Ongoing research into novel monoclonal antibody agents promises further advancements in cancer therapy.